

Novel Inflammatory Biomarkers in Patients with Mycosis Fungoides Treated with Bexarotene

Funda Tamer and Ayla Gulekon

Department of Dermatology, Gazi University School of Medicine, Ankara, Turkey

ABSTRACT

Mycosis fungoides (MF) is a skin lymphoma characterised by atypical T lymphocyte infiltration, which may present with patches and tumors in advanced stages. Treatment options in MF aim to reduce symptoms, since patients usually do not achieve complete cure. Bexarotene is used for treatment-resistant early stage MF and advanced stages of the disease. It has been suggested that white blood cell (WBC)/absolute lymphocyte count, WBC, absolute lymphocyte and eosinophil counts might be prognostic factors in MF. Therefore, we investigated the changes in complete blood count (CBC) parameters and CBC-derived inflammatory biomarkers in patients with MF treated with bexarotene. The results revealed that neutrophil (NE)%, NE numbers, neutrophil/lymphocyte, derived neutrophil/lymphocyte, (neutrophil \times monocytes)/lymphocyte and (neutrophils \times monocytes \times platelets)/lymphocyte counts decreased in all patients three months after bexarotene treatment. We suggest that these inflammatory biomarkers can be used in the follow-up of patients with MF receiving bexarotene treatment. Moreover, these results indicate that decrease in these inflammatory biomarkers may signify improvement of the disease.

Key Words: Bexarotene, Inflammatory biomarkers, Mycosis fungoides.

How to cite this article: Tamer F, Gulekon A. Novel Inflammatory Biomarkers in Patients with Mycosis Fungoides Treated with Bexarotene. *J Coll Physicians Surg Pak* 2021; **31(06)**:716-718.

INTRODUCTION

Mycosis fungoides (MF) is a skin lymphoma originating from epidermotropic clonal T-lymphocytes. It occurs in 5.6 cases per million; however, the incidence increases with age.¹ MF predominantly affects elderly patients over the age of 70 years. MF usually starts as eczema-like lesions, while advanced stages present with tumors or leukemic transformation. Treatment options aim to reduce symptoms and prevent disease progression. Nevertheless, patients usually do not achieve complete cure.¹ Treating MF is based on the disease stage and efficacy of previous treatments. Bexarotene is a synthetic retinoid which is used to treat advanced disease. It is also effective in treatment-resistant cases of early stage MF.² Bexarotene causes apoptosis of atypical T lymphocytes. However, the mechanism of action of bexarotene has not been fully understood.³

It has been suggested that complete blood count (CBC) parameters might provide prognostic clues in patients with MF. Increases in white blood cell (WBC), absolute lymphocyte and eosinophil counts have been associated with progressive disease.⁴

In the light of this information, we investigated the effect of bexarotene treatment on CBC and CBC-derived inflammatory biomarkers in patients with MF. The outcomes may suggest novel markers to be used in the follow-up of patients with MF to evaluate the improvement of the disease.

CASE REPORT

Hereby, we report five patients who received systemic bexarotene for the treatment of biopsy-proven MF. Patients' age, gender, disease duration, disease localisation, type of MF, lymph node involvement and stage of the disease were examined (Table I). The stage of the disease was defined based on TNMB classification.¹ The patients received bexarotene capsules, 300 mg/m²/day. The patients achieved partial response 12 weeks after bexarotene treatment. Inflammatory biomarkers that we analysed were neutrophil/lymphocyte count (N/L), monocyte/lymphocyte count (M/L), platelet/lymphocyte count (PLT/L), mean platelet volume/platelet count (MPV/PLT), derived neutrophil/lymphocyte count [neutrophils/(WBC-neutrophils)] (DNLR), (neutrophils \times monocytes)/lymphocyte count (N \times M/L) and (neutrophils \times monocytes \times platelets)/lymphocyte count (N \times M \times P/L).^{5,6}

The results revealed that lymphocyte percentage (%) increased while neutrophil (NE)% and neutrophil numbers (NE#) decreased in all patients after bexarotene treatment. The rest of CBC parameters did not change significantly. Nevertheless, WBC count decreased in four patients and stayed same in one patient. Leukopenia was observed in only one patient after bexarotene treatment.

Correspondence to: Dr. Funda Tamer, Department of Dermatology, Gazi University School of Medicine, Ankara, Turkey

E-mail: fundatmr@yahoo.com

Received: October 03, 2019; Revised: December 28, 2019;

Accepted: January 20, 2021

DOI: <https://doi.org/10.29271/jcpsp.2021.06.716>

Table I: Demographics and disease characteristics of the patients.

Age/ Gender	Disease duration (years)	Localisation	MF variants	Sezary cells	Lymph nodes	MF stage
43/ M	6	face, trunk, extremities	large-cell transformation	N	left axillary	IVA (T2,N3,M0,B0)
55/ F	15	trunk, extremities	classic	N	bilateral inguinal	IIA (T2,N1,M0,B0)
49/ M	25	trunk	poikilodermatous	N	bilateral cervical	IIA (T2,N1,M0,B0)
70/ M	6	face, trunk, extremities	folliculotropic	<5%	-	IIB (T3, N0,M0,B0)
62/ M	3	erythrodermic	erythrodermic	N	bilateral inguinal	IVA (T4,N1,M0,B0)

F: Female, M: Male, MF: Mycosis fungoides, N: The absence of Sezary cells, <5% : <5% of peripheral blood lymphocytes were atypical Sezary cells.

Table II: Hemogram parameters of the patients before and three months after bexarotene treatment.

	Patient 1		Patient 2		Patient 3		Patient 4		Patient 5	
	Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment
WBC (x10 ³ /μL)	5.6	3.5	8.3	6.5	9.8	6.2	6.7	6.7	12.4	8
PLT (x10 ³ /μL)	249	351	222.6	322	236	245	273	254	304	154
MPV (fL)	8.8	7.9	8.6	8.2	10.1	10.3	10.5	10.9	9	11.5
LY%	21.3	25.7	25.1	40	33.6	38	20.9	32.4	16.1	21
MO%	7.6	9.2	6.6	7.9	6.8	10.8	7.8	6.8	6.1	3.5
NE%	68.7	60.2	66.6	49	52.9	46.3	70.1	58.6	76.5	74.2
EO%	1.7	2.4	1.2	2.2	5.6	3.8	0.9	1.6	1.1	0.9
BA%	0.7	2.3	0.3	0.6	1.1	1.1	0.3	0.6	0.2	0.4
LY# (x10 ³ /μL)	1.2	0.9	2.1	2.6	3.3	2.3	1.4	2.1	2	1.7
MO# (x10 ³ /μL)	0.4	0.3	0.5	0.5	0.6	0.6	0.5	0.4	0.7	0.2
NE# (x10 ³ /μL)	3.9	2.1	5.5	3.2	5.2	2.9	4.7	3.9	9.4	6
EO# (x10 ³ /μL)	0.1	0.08	0.1	0.1	0.5	0.2	0.06	0.1	0.1	0.07
BA# (x10 ³ /μL)	0.06	0.08	0.03	0.04	0.1	0.07	0.02	0.04	0.03	0.03

The percentages of lymphocytes (LY%), monocytes (MO%), neutrophils (NE%), eosinophils (EO%), basophils (BA%). LY% increased while NE% and NE# decreased in all patients after bexarotene treatment. WBC decreased in four patients and stayed same in one patient.
 MPV: Mean platelet volume (reference range: 9.1-11.9fL), PLT: Platelet (reference range: 173-390x10³/μL), WBC: White blood cell (reference range: 4.49-12.68x10³/μL), Absolute counts of lymphocytes (LY#), monocytes (MO#), neutrophils (NE#), eosinophils (EO#), basophils (BA#).

Table III: Inflammatory biomarkers before and three months after bexarotene treatment.

	Patient 1		Patient 2		Patient 3		Patient 4		Patient 5	
	Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment	Before treatment	After treatment
N/L	3.2	2.3	2.6	1.2	1.5	1.2	3.3	1.8	4.7	3.5
M/L	0.3	0.3	0.2	0.1	0.1	0.2	0.3	0.1	0.3	0.1
PLT/L	207.5	390	106	123.8	71.5	106.5	195	120.9	152	90.5
MPV/PLT	0.035	0.022	0.038	0.025	0.042	0.042	0.038	0.042	0.029	0.074
DNLR	2.29	1.5	1.96	0.94	1.13	0.86	2.35	1.38	3.13	2.88
NXM/L	1.3	0.7	1.3	0.6	0.94	0.75	1.67	0.74	3.29	0.66
NXMP/L	323.7	245.7	289.3	193.2	221.8	183.7	455.9	187.9	1000.1	101.6

DNLR: derived neutrophil / lymphocyte [neutrophils / (white blood cells - neutrophils)], M/L: monocyte / lymphocyte, MPV/PLT: mean platelet volume / platelet count (fL10⁻³μL⁻¹), N/L: neutrophil / lymphocyte, NXM/L: (neutrophils x monocytes) / lymphocyte, NXMP/L: (neutrophils x monocytes x platelets) / lymphocyte, PLT/L: platelet / lymphocyte.
 N/L, DNLR, NXM/L and NXMP/L were decreased in all patients three months after bexarotene treatment.

Within this study, N/L, DNLR, N×M/L and N×M×P/L decreased in all patients three months after bexarotene treatment. However, M/L decreased in three patients, increased in one and stayed same in one patient. PLT/L increased in three and decreased in two patients. MPV/PLT increased in two patients, decreased in two and stayed same in one patient. CBC parameters and CBC-derived inflammatory biomarkers of the patients before and three months after bexarotene treatment are shown in Tables II and III.

DISCUSSION

Bexarotene is a safe and successful choice for the management of cutaneous T-cell lymphoma (CTCL). Bexarotene facilitates atypical T lymphocyte apoptosis sparing the cutaneous T-regulatory cells. Hypertriglyceridemia and hypothyroidism are well documented side effects of systemic bexarotene treatment.⁷

Furthermore, Abbott *et al.* reported leukopenia and neutropenia after bexarotene treatment for CTCL.⁸ Duvic *et al.* reported leukopenia in 11% of the patients who received bexarotene. Leukopenia was observed as a result of decreased polymorphonuclear leukocyte count.⁹ Within this study, WBC count decreased in four patients; however, WBC counts were within normal limits in these patients except for one. As a result, leukopenia was observed only in one patient. Furthermore, hypertriglyceridemia and hypothyroidism were observed in all patients after bexarotene treatment. However, these side effects did not lead to cessation of the bexarotene treatment.

Disease severity, systemic involvement, efficacy of treatment, histological transformation and high serum lactate dehydrogenase (LDH) levels can be used to determine the prognosis of CTCL. Tancredi-Bohin *et al.* reported that raised absolute eosinophil count might be associated with disease progression

in CTCL. Furthermore, elevated WBC, absolute lymphocyte and eosinophil counts and WBC/absolute lymphocyte count have been associated with increased risk for progression and mortality in MF.^{4,10,11} Ozbagicvan investigated the prognostic value of mean platelet volume (MPV) in early stage MF; however, no correlation was detected between MPV and disease progression during the 5-year follow-up of patients.¹² Response to bexarotene treatment is usually obtained within two months.⁹ Therefore, we evaluated the alteration in CBC parameters and CBC-derived inflammatory biomarkers in MF patients after three months of treatment with bexarotene. Among the prognostic factors which were reported previously, we detected decreased WBC counts in four patients. However, all patients showed decreased NE% and NE # after bexarotene treatment. As peripheral blood neutrophil activation has been implicated in MF pathophysiology, bexarotene may have an effect through neutrophils in the treatment of the disease.¹³

CBC-derived inflammatory biomarkers have been investigated in various solid tumors and hematological malignancies including multiple myeloma, non-Hodgkin lymphoma and diffuse large B-cell lymphoma. However, prognostic role of CBC-derived inflammatory biomarkers in MF still remains controversial.^{12,14} It has been proposed that high N/L and PLT/L levels were related to progressive disease.¹² On the other hand, Eren *et al.* reported no correlation between N/L and disease progression, time to progression or treatment demand. However, a few studies have been reported in the medical literature investigating inflammatory biomarkers in MF.¹⁴ Our results revealed that bexarotene led to decrease in N/L, DNLR, N×M/L and N×M×P/L in patients with MF. Decrease in these inflammatory biomarkers may signify improvement of the disease. Therefore, we suggest that decrease in N/L, DNLR, N×M/L and N×M×P/L may be helpful in the follow-up of patients who are diagnosed with MF and treated with bexarotene. Furthermore, N/L, DNLR, N×M/L and N×M×P/L may be regarded as prognostic factors in MF. However, larger clinical studies are required for the confirmation of these results.

PATIENTS' CONSENT:

Informed consents were obtained from the patients.

CONFLICT OF INTEREST:

The authors declared no conflict of interest.

AUTHORS' CONTRIBUTION:

FT: Design of the manuscript, analysis of data for the manuscript, literature search, drafting and revising the intellectual content of the manuscript, final approval, agreement to be accountable for all aspects of the manuscript.

AG: Design of the manuscript, drafting and revising the intellectual content of the manuscript, final approval, agreement to be accountable for all aspects of the manuscript.

REFERENCES

1. Larocca C, Kupper T. Mycosis fungoides and Sézary

syndrome: An update. *Hematol Oncol Clin North Am* 2019; **33(1)**:103-20. Doi: 10.1016/j.hoc.2018.09.001.

2. Panchal MR, Scarisbrick JJ. The utility of bexarotene in mycosis fungoides and Sézary syndrome. *Onco Targets Ther* 2015; **8**:367-73. Doi: 10.2147/OTT.S61308.
3. Schadt CR. Topical and oral bexarotene. *Dermatol Ther* 2013; **26(5)**:400-3. Doi: 10.1111/dth.12087.
4. Dulmage B, Geskin L, Guitart J, Akilov OE. The biomarker landscape in mycosis fungoides and Sézary syndrome. *Exp Dermatol* 2017; **26(8)**:668-76. Doi: 10.1111/exd.13261.
5. Djordjevic D, Rondovic G, Surbatovic M, Stanojevic I, Udovicic I, Andjelic T, *et al.* Neutrophil-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and mean platelet volume-to-platelet count ratio as biomarkers in critically ill and injured patients: Which ratio to choose to predict outcome and nature of bacteremia? *Mediators Inflamm* 2018; **2018**:3758068. Doi: 10.1155/2018/3758068.
6. Pinna A, Porcu T, D'Amico-Ricci G, Dore S, Boscia F, Palio-giannis P, *et al.* Complete blood cell count-derived inflammation biomarkers in men with age-related macular degeneration. *Ocul Immunol Inflamm* 2019; **27(6)**:932-6. Doi: 10.1080/09273948.2018.1485960.
7. Väkevää L, Ranki A, Hahtola S. Ten-year experience of bexarotene therapy for cutaneous T-cell lymphoma in Finland. *Acta Derm Venereol* 2012; **92(3)**:258-63. Doi: 10.2340/00015555-1359.
8. Abbott RA, Whittaker SJ, Morris SL, Russell-Jones R, Hung T, Bashir SJ, *et al.* Bexarotene therapy for mycosis fungoides and Sézary syndrome. *Br J Dermatol* 2009; **160(6)**: 1299-307. Doi: 10.1111/j.1365-2133.2009.09037.x.
9. Duvic M, Hymes K, Heald P, Breneman D, Martin AG, Myskowski P, *et al.* Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: Multinational phase II-III trial results. *J Clin Oncol* 2001; **19(9)**:2456-71. Doi: 10.1200/JCO.2001.19.9.2456.
10. Tancrede-Bohin E, Ionescu MA, de La Salmonière P, Dupuy A, Rivet J, Rybojad M, *et al.* Prognostic value of blood eosinophilia in primary cutaneous T-cell lymphomas. *Arch Dermatol* 2004; **140(9)**:1057-61. Doi: 10.1001/archderm.140.9.1057.
11. Scarisbrick JJ, Prince HM, Vermeer MH, Quaglini P, Horwitz S, Porcu P, *et al.* Cutaneous lymphoma international consortium study of outcome in advanced stages of mycosis fungoides and Sézary syndrome: Effect of specific prognostic markers on survival and development of a prognostic model. *J Clin Oncol* 2015; **33(32)**:3766-73. Doi: 10.1200/JCO.2015.61.7142.
12. Ozbagicvan O. Prognostic significance of neutrophil/lymphocyte ratio, platelet/lymphocyte ratio and mean platelet volume in the early stage mycosis fungoides. *Dokuz Eylul Universitesi Tip Fakultesi Dergisi* 2019; **33(2)**:149-57. Doi: 10.5505/deutfd.2019.55706.
13. Goddard DS, Yamanaka K, Kupper TS, Jones DA. Activation of neutrophils in cutaneous T-cell lymphoma. *Clin Cancer Res* 2005; **11(23)**:8243-9. Doi: 10.1158/1078-0432.CCR-05-1434.
14. Eren R, Nizam N, Doğu MH, Mercan S, Erdemir AV, Suyanı E. Evaluation of neutrophil-lymphocyte ratio in patients with early-stage mycosis fungoides. *Ann Hematol* 2016; **95(11)**:1853-7. Doi: 10.1007/s00277-016-2779-7.

